NEW YORK – After publishing promising early data, investigators from Washington University in St. Louis plan to further validate the use of liquid biopsy-based minimal residual disease detection in oligometastatic colorectal cancer patients — individuals with cancers that have begun to seed new lesions in a small number of nearby sites but not yet widely through the whole body.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.